In a significant leap forward for emergency medical response, Micron Biomedical has secured a $4.5 million contract from the National Institute of Allergy and Infectious Diseases (NIAID). This federal investment, funneled through the institute’s prestigious Radiation and Nuclear Countermeasures Program, marks a pivotal milestone in the development of a revolutionary, needle-free drug delivery platform designed to combat Acute Radiation Syndrome (ARS).
The collaboration, announced on July 27, pairs Micron’s proprietary dissolvable microarray technology with Connext’s potent TLR5 agonist, xempritolimod. Together, these entities are working to solve one of the most pressing challenges in public health security: how to rapidly and effectively deliver life-saving therapeutics to a population following a mass-exposure radiation event.
The Core Innovation: A "Button" for Life-Saving Medicine
At the heart of the partnership is a device that reimagines the act of medical administration. Micron Biomedical has developed what CEO Steven Damon describes as a "button"—a compact, microarray-based patch that can be applied to the back of a patient’s wrist.
The mechanism is deceptively simple: upon application, the user or a caregiver presses the button, releasing the medication into the upper layers of the skin. Because the microscopic projections target only the superficial skin layers—avoiding the deeper, nerve-rich tissues—the process is virtually painless. Once the medicine is delivered, the patch is discarded as simple, sharps-free waste.
"If something happened, we’d be able to quickly get it to that location and to those people, and they’d be able to self-administer it," Damon stated in an interview with Drug Discovery and Development. "It would allow a fast response."
A Chronology of Innovation: From Georgia Tech to the Global Stage
The journey to this $4.5 million federal contract began within the academic halls of the Georgia Institute of Technology. The core technology, which utilizes dissolvable microneedles to penetrate the skin barrier, originated in the lab of Dr. Mark Prausnitz, a pioneer in transdermal delivery systems.
Following the development of this foundational research, Micron Biomedical was co-founded by Prausnitz, alongside Devin McAllister and Sebastien Henry. By licensing the intellectual property from Georgia Tech, the company set out to transform a laboratory concept into a scalable, commercial reality.
Key Milestones in the Development Pipeline:
- Initial Research: Development of micro-molded templates and the vacuum-assisted casting process to ensure precision in drug distribution within the needle cavities.
- Clinical Validation: A high-profile study published in The Lancet tested the patches against three strains of influenza. The data revealed numerically higher seroconversion rates—a key marker of immune response—compared to traditional intramuscular injections. Most notably, for the B-strain of influenza, the patch achieved a 71% seroconversion rate at 28 days, compared to 32% for the injection.
- The CEPI Partnership: Micron entered a separate, high-stakes partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). This initiative is focused on applying the platform to CastleVax’s rapid-response vaccine architecture, aiming to dramatically compress timelines for future pandemic threats.
- NIAID Contract: The July 2026 award represents the latest phase of the company’s evolution, moving beyond vaccine delivery into the specialized, high-stakes realm of nuclear and radiological defense.
Technical Superiority and Manufacturing Realities
The manufacturing process is as innovative as the product itself. To create these patches, Micron formulates medication into a liquid solution, which is then cast onto a micro-molded template. A vacuum is applied beneath the mold to draw the solution into the microscopic cavities, effectively eliminating air bubbles that could compromise dosage. The mold is then dried, solidifying the drug and creating a thermostable product that does not require cold-chain storage.
This thermostability is a critical feature for national security. Traditional vaccines and injectable medicines often require specialized refrigeration, creating logistical bottlenecks during a crisis. Micron’s patch, conversely, can be stockpiled in warehouses indefinitely and deployed rapidly to areas with damaged infrastructure.
"The key to improving that timeline was building out manufacturing," Damon noted. "We actually had to invent the equipment, and that equipment is being built domestically. Facilities and manufacturing for commercial-scale production are essential."
The Strategic Implications of the NIAID Contract
The partnership with Connext is not merely about a single drug; it is a test case for how the United States might handle a potential nuclear or radiological emergency. Acute Radiation Syndrome (ARS) is a life-threatening illness caused by high-dose radiation exposure. The effectiveness of treatment depends entirely on the speed of intervention.
Strategic Advantages for Defense:
- Deployment Speed: Because the patches are thermostable, they can be pre-positioned in vulnerable urban centers or near nuclear facilities, bypassing the delays associated with the cold-chain distribution of standard medications.
- Accessibility: The simplicity of the "push-button" design allows for self-administration or administration by individuals with minimal medical training. This empowers victims to treat themselves in the chaotic aftermath of an event, rather than overwhelming a compromised healthcare system.
- Sustainability: The device is discarded as standard waste, eliminating the risks associated with sharp biohazards in a high-pressure environment.
Scaling the Future: Beyond Radiation Countermeasures
While the NIAID contract focuses on radiation, the implications for the technology are far broader. Micron Biomedical is currently balancing its regulatory strategy with the practical demands of scaling production. The company is actively pursuing FDA approval for its platform, aiming to follow a dual-track strategy: applying the delivery technology to already-approved drugs to expedite market entry, while simultaneously moving novel therapeutics through clinical trials.
CEO Steven Damon is clear about the company’s trajectory. "We’re dose-limited, but within that limit, we can handle many, many drugs," he explained. The company is exploring the application of the technology for weight-loss medications and a host of other injectable therapies.
Furthermore, the impact on low-income nations cannot be overstated. In regions where cold-chain infrastructure is non-existent, the ability to distribute medicine via simple, disposable patches could revolutionize public health. "They don’t need a doctor to administer it," Damon said. "They can self-administer it, or a mom can administer it to her child… it can be put on a moped and driven into villages that don’t have access."
Looking Ahead: The 2028 Target
Micron Biomedical is aggressively working toward a 2028 target for its first commercial product launch. As the company refines its manufacturing processes, its primary focus remains on proving the platform’s reliability to the FDA.
The convergence of government funding, private-sector innovation, and a clear, modular platform design positions Micron Biomedical as a significant player in the future of drug delivery. Whether for the next pandemic, a localized disease outbreak, or a large-scale biosecurity event, the "button" patch represents a shift toward a more resilient, accessible, and decentralized medical infrastructure.
As the company moves into the next phase of its NIAID-funded research, the global health community will be watching closely. If Micron can successfully navigate the manufacturing and regulatory hurdles, they may well succeed in making the traditional syringe a relic of the past, replaced by a simple, painless patch that can be deployed anywhere, by anyone, at any time.
About the Author
